ClinicalTrials.gg
CompletedNCT02387554Updated Jun 12, 2015Results posted

Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405

A Phase 1 interventional study of HGP0904 and HGP0608 in Hypertension(HTN), sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-12.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
163rd of 186
33 · median 180
Started
2014
with 11 others
Phase 1
17 of 187
none open now
Registered
124th of 187
by date
Lead sponsor
6 of 187
Hanmi Pharmaceutical Company Limited

Among the 187 studies testing amlodipine in Hypertension, this one is the 163rd largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2014, is one of 17 in phase 1, and was the 124th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers

03

Conditions studied

  • Hypertension(HTN)

Browse trials for

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19\~45 years old
  • Healthy men

Exclusion criteria

Exclusion Criteria:

  • Gastroentestinal disease affecting drug absorption
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    HGP0904+HGP0608+HGP1405

    amlodipine + losartan + chlorthalidone

    Drug: HGP0904 · Drug: HGP0608 · Drug: HGP1405

  • Active comparator
    HGP0904

    amlodipine

    Drug: HGP0904

  • Active comparator
    HGP0608

    losartan

    Drug: HGP0608

  • Active comparator
    HGP1405

    chlorthalidone

    Drug: HGP1405

Interventions

  • Also known as: amlodipine

  • Also known as: losartan

  • Also known as: chlorthalidone

06

What researchers measure

Primary outcomes

  1. AUClast

    AUClast(Area under the curve to the last measurable concentration)

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

  2. Cmax

    Cmax(maxium concentration)

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Secondary outcomes

  1. AUCinf

    AUCinf(Area under the curve to infinity)

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

  2. Tmax

    Tmax(Time to maximum concentration)

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

  3. T1/2

    T1/2(Terminal elimination half-life),

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

  4. CL/F

    CL/F(Apparent clearance)

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

  5. Vz/F

    Vz/F(Apparent volume of distribution)

    Time frame: 0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Other outcomes

  1. Number of Paticipants With Adverse Events

    Time frame: 3 months

07

Results

Posted Jun 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started10788
Completed7766
Not completed3022

Outcome measures

PrimaryAUClast

AUClast(Area under the curve to the last measurable concentration)

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr
Reported as:
Geometric mean · Ratio(Comb/Alone)
AUClast
Ratio(Comb/Alone)HGP0904HGP0608HGP1405EXP3174
AUClast1.0360 (0.9958 to 1.0778)1.1606 (1.0885 to 1.2375)1.0266 (0.9752 to 1.0807)1.0902 (1.0350 to 1.1148)
PrimaryCmax

Cmax(maxium concentration)

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Results for this outcome have not been posted.

SecondaryAUCinf

AUCinf(Area under the curve to infinity)

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Results for this outcome have not been posted.

SecondaryTmax

Tmax(Time to maximum concentration)

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Results for this outcome have not been posted.

SecondaryT1/2

T1/2(Terminal elimination half-life),

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Results for this outcome have not been posted.

SecondaryCL/F

CL/F(Apparent clearance)

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Results for this outcome have not been posted.

SecondaryVz/F

Vz/F(Apparent volume of distribution)

Time frame:
0, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96, 120, 168hr

Results for this outcome have not been posted.

Other pre-specifiedNumber of Paticipants With Adverse Events
Time frame:
3 months

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HGP0904—1/28 (3.6%)0/28 (0%)
HGP0608—0/27 (0%)0/27 (0%)
HGP1405—0/27 (0%)0/27 (0%)
HGP0904+HGP0608+HGP1405—0/28 (0%)2/28 (7.1%)
Most frequent serious events
Most frequent serious events
EventHGP0904HGP0608HGP1405HGP0904+HGP0608+HGP1405
MeningitisInfections and infestations1/280/270/270/28
Most frequent other events
Most frequent other events
EventHGP0904HGP0608HGP1405HGP0904+HGP0608+HGP1405
NauseaGastrointestinal disorders0/280/270/272/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence 1Sequence 2Sequence 3Sequence 4Total
Mean26.70 ± 4.0626.43 ± 4.8926.00 ± 3.9324.88 ± 4.0526.06 ± 4.07
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Female00000
Male1078833
Region of Enrollment
Region of Enrollment(participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Korea, Republic of1078833
08

Study locations

1 site
  • Seoul National University Bundang Hospital
    Bundang, Gyeonggi, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2014
First posted
Mar 13, 2015
Start
Aug 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Jun 12, 2015
Last update
Jun 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02387554
Responsible party
Sponsor
First posted
Mar 13, 2015
Start date
Aug 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Jun 12, 2015
Last update
Jun 12, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · HGP0608 · Losartan

Start the discussion